 Connection
Jose Castillo-Mancilla to HIV-1
This is a "connection" page, showing publications Jose Castillo-Mancilla has written about HIV-1.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.965 |
|
|
|
-
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR. Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. HIV Med. 2026 Mar; 27(3):386-396.
Score: 0.601
-
Mann SC, Morrow M, Coyle RP, Coleman SS, Saderup A, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL, Castillo-Mancilla JR. Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. J Acquir Immune Defic Syndr. 2020 12 01; 85(4):483-488.
Score: 0.424
-
Rogg L, Underwood M, Hanan N, Castillo-Mancilla JR, Kahl L, Halliday F, Ghita GL, Jeffrey JL, Byrne S, Onodera T, Horton J, Gartland M. Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2025 Oct 06; 81(3):510-520.
Score: 0.148
-
Castillo JR, Kirchner E, Farver C, Calabrese LH. Cryoglobulinemic vasculitis and lymphocytic interstitial pneumonitis in a person with HIV infection. AIDS Read. 2005 May; 15(5):252-5.
Score: 0.144
-
Mann SC, Tong W, Abraham AG, Palella F, Sharma A, Tien PC, Fischl MA, McFarlane SI, Lahiri CD, Koletar S, Merenstein D, Floris-Moore M, Lake JE, Daubert E, Hickman A, Brown TT, Castillo-Mancilla J. The impact of diabetes mellitus on HIV virologic control: results of the MACS/WIHS combined cohort study. AIDS. 2024 11 15; 38(14):1922-1931.
Score: 0.136
-
Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Crain CR, Traunbauer AK, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Dorazio D, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Sieg S, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZ. Viral and host mediators of non-suppressible HIV-1 viremia. Nat Med. 2023 12; 29(12):3212-3223.
Score: 0.130
-
Singh Y, Castillo-Mancilla J, Madimabe R, Jennings L, Ferraris CM, Robbins RN, Anderson PL, Remien RH, Orrell C. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa. AIDS Res Ther. 2023 09 14; 20(1):67.
Score: 0.128
-
Pandey S, Hu Y, Bushman LR, Castillo-Mancilla J, Anderson PL, Cooks RG. Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood. Anal Bioanal Chem. 2022 May; 414(11):3387-3395.
Score: 0.115
-
Siedner MJ, Bwana MB, Asiimwe S, Amanyire G, Musinguzi N, Castillo-Mancilla J, Tracy RP, Katz IT, Bangsberg DR, Hunt PW, Orrell C, Haberer JE. Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study. J Infect Dis. 2019 08 30; 220(7):1172-1177.
Score: 0.097
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
Score: 0.022
-
Chen X, Castillo-Mancilla JR, Seifert SM, McAllister KB, Zheng JH, Bushman LR, MaWhinney S, Anderson PL. Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother. 2016 09; 60(9):5387-92.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|